Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.
Adult
Aged
Aminobutyrates
/ economics
Attitude of Health Personnel
Biphenyl Compounds
Cardiovascular Agents
/ economics
Choice Behavior
Decision Making, Shared
Drug Combinations
Drug Costs
Female
Health Expenditures
Health Knowledge, Attitudes, Practice
Heart Failure
/ diagnosis
Humans
Interviews as Topic
Male
Middle Aged
Patient Participation
Patient Preference
Patient-Centered Care
Physician-Patient Relations
Tetrazoles
/ economics
Valsartan
decision-making
heart failure
outpatients
patient preferences
patient-centered care
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
13
11
2020
medline:
16
3
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
Discussions of medication costs between patients and clinicians are infrequent and often suboptimal. In the context of recently introduced drugs that are effective but expensive, patients with heart failure with reduced ejection fraction provide an ideal population to understand the perspectives of patients with chronic illness on medication cost and cost discussions. To explore patients' perspectives on discussing out-of-pocket medication costs with clinicians, 49 adults, aged 44 to 70 years, with heart failure with reduced ejection fraction were recruited from outpatient heart failure clinics. Descriptive qualitative analysis was performed on open-ended text data. Participants who had prior medication-related cost discussions described their experience as generally positive, but about half of the participants had never had a cost discussion with their clinician. Most participants were open to cost discussions with clinicians and preferred that the clinician initiate discussions regarding medication cost. Importantly, these preferences held constant across reported levels of financial burden. These data suggest a substantial willingness on the part of patients with heart failure with reduced ejection fraction to incorporate cost discussions into their care and identify important aspects of these discussions for clinicians to consider when engaging in conversations where cost is relevant. Improving understanding about how to integrate patient preferences regarding cost discussions into clinical encounters is an important priority for advancing patient-centered care.
Sections du résumé
BACKGROUND
Discussions of medication costs between patients and clinicians are infrequent and often suboptimal. In the context of recently introduced drugs that are effective but expensive, patients with heart failure with reduced ejection fraction provide an ideal population to understand the perspectives of patients with chronic illness on medication cost and cost discussions.
METHODS
To explore patients' perspectives on discussing out-of-pocket medication costs with clinicians, 49 adults, aged 44 to 70 years, with heart failure with reduced ejection fraction were recruited from outpatient heart failure clinics. Descriptive qualitative analysis was performed on open-ended text data.
RESULTS
Participants who had prior medication-related cost discussions described their experience as generally positive, but about half of the participants had never had a cost discussion with their clinician. Most participants were open to cost discussions with clinicians and preferred that the clinician initiate discussions regarding medication cost. Importantly, these preferences held constant across reported levels of financial burden.
CONCLUSIONS
These data suggest a substantial willingness on the part of patients with heart failure with reduced ejection fraction to incorporate cost discussions into their care and identify important aspects of these discussions for clinicians to consider when engaging in conversations where cost is relevant. Improving understanding about how to integrate patient preferences regarding cost discussions into clinical encounters is an important priority for advancing patient-centered care.
Identifiants
pubmed: 33176459
doi: 10.1161/CIRCHEARTFAILURE.120.007094
pmc: PMC7982995
mid: NIHMS1677251
doi:
Substances chimiques
Aminobutyrates
0
Biphenyl Compounds
0
Cardiovascular Agents
0
Drug Combinations
0
Tetrazoles
0
Valsartan
80M03YXJ7I
sacubitril and valsartan sodium hydrate drug combination
WB8FT61183
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e007094Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR002382
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
J Am Heart Assoc. 2019 Jan 8;8(1):e010635
pubmed: 30592239
J Gen Intern Med. 2006 Aug;21(8):874-7
pubmed: 16881950
Res Nurs Health. 2000 Aug;23(4):334-40
pubmed: 10940958
Circulation. 2015 Oct 6;132(14):1347-53
pubmed: 26316616
Arch Intern Med. 2002 Nov 11;162(20):2269-76
pubmed: 12418941
Ann Intern Med. 2019 May 7;170(9_Suppl):S87-S92
pubmed: 31060054
Heart Rhythm. 2013 Apr;10(4):e59-65
pubmed: 23403056
Circ Heart Fail. 2018 Feb;11(2):e004302
pubmed: 29453287
N Engl J Med. 2013 Oct 17;369(16):1484-6
pubmed: 24131175
JAMA Cardiol. 2019 Aug 1;4(8):828-830
pubmed: 31290933
Circulation. 2016 Sep 27;134(13):e282-93
pubmed: 27208050
Ann Intern Med. 2019 May 7;170(9_Suppl):S33-S35
pubmed: 31060062
Ann Intern Med. 2019 May 7;170(9_Suppl):S93-S102
pubmed: 31060060
J Gen Intern Med. 2004 Aug;19(8):856-60
pubmed: 15242471
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
N Engl J Med. 2018 Dec 13;379(24):2290-2293
pubmed: 30428275
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
Oncologist. 2014 Nov;19(11):1135-40
pubmed: 25273078
Health Aff (Millwood). 2016 Apr;35(4):654-61
pubmed: 27044966